Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 11:12:80-88.
doi: 10.33393/grhta.2025.3365. eCollection 2025 Jan-Dec.

Assessing the economic burden of Waldenström's Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)

Matteo Scortichini  1 , Martina Paoletti  1 , Angela Ragonese  1 , Antonio Cuneo  2 , Marco Vignetti  3 , Pier Luigi Zinzani  4   5
Affiliations

Assessing the economic burden of Waldenström's Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)

Matteo Scortichini et al. Glob Reg Health Technol Assess. .

Abstract

Introduction: In Italy, Non-Hodgkin Lymphomas (NHL), including Waldenström's Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL), are among the most common hematologic cancers. These conditions mainly affect the elderly, who often have multiple comorbidities, complicating management and imposing significant burdens on patient quality of life and healthcare systems.

Objective: This study aimed to estimate the economic burden of selected B-cell lymphomas in Italy, providing insights for decision-makers to improve patient management and resource allocation.

Method: Data from the Italian Hospital Discharges Records (SDO) and the National Institute for Social Security were analyzed to estimate direct healthcare costs and social security costs from 2016 to 2019.

Results: A total of 93,712 hospital discharges were recorded, with MZL being the most common diagnosis, followed by CLL and WM. Most patients were male, and the 70-79 age group was most prevalent. MZL had the highest costs, followed by CLL and WM. Adverse events notably increased total expenditures, with variations across different pathologies. Direct healthcare costs totaled 533.6 million euros, while social security costs amounted to 240.9 million euros.

Conclusion: This study highlights the significant economic burden of selected B-cell lymphomas in Italy. Effective management strategies are crucial for reducing costs and optimizing resource allocation in the healthcare system.

Keywords: Chronic Lymphocytic Leukemia (CLL); Direct costs; Economic Burden; Indirect costs; Italy; Marginal Zone Lymphoma (MZL); Real-World Evidence; Waldenström’s Macroglobulinemia (WM).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no relevant financial or non-financial interests to disclose.

Figures

FIGURE 1 -
FIGURE 1 -
Mean monthly cumulated cost per patient with CLL. CLL: chronic lymphocytic leukemia
FIGURE 2 -
FIGURE 2 -
Mean monthly cumulated cost per patient with MZL. MZL: marginal zone lymphoma
FIGURE 3 -
FIGURE 3 -
Mean monthly cumulated cost per patient with WM. WM: Waldenström’s macroglobulinemia
FIGURE 4 -
FIGURE 4 -
Annual trend of estimated prevalent beneficiaries of social security benefits, by type of recognition and pathology CLL: chronic lymphocytic leukemia; MZL: marginal zone lymphoma
See this image and copyright information in PMC

References

    1. Thandra KC, Barsouk A, Saginala K et al. Epidemiology of Non-Hodgkin’s Lymphoma. Vol. 9, Medical sciences (Basel, Switzerland). 2021 doi: 10.3390/medsci9010005. - DOI - PMC - PubMed
    1. Mafra A, Laversanne M, Gospodarowicz M et al. Global patterns of non-Hodgkin lymphoma in 2020. Int J Cancer. 2022;151(9):1474–1481. doi: 10.1002/ijc.34163. - DOI - PubMed
    1. AIOM AIRTUM. I numeri del cancro in Italia 2023. [Accessed October; 2024 ]. Online
    1. Castillo JJ, Olszewski AJ, Cronin AM et al. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014;123(25):3999–4000. doi: 10.1182/blood-2014-05-574871. - DOI - PubMed
    1. Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M. Waldenström’s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24(SUPPL.6) doi: 10.1093/annonc/mdt298. - DOI - PubMed

LinkOut - more resources